Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 677,504
  • Shares Outstanding, K 48,882
  • Annual Sales, $ 30,430 K
  • Annual Income, $ -85,340 K
  • 60-Month Beta 2.82
  • Price/Sales 15.91
  • Price/Cash Flow N/A
  • Price/Book 2.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.54
  • Number of Estimates 7
  • High Estimate -0.47
  • Low Estimate -0.65
  • Prior Year -0.43
  • Growth Rate Est. (year over year) -25.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.87 +13.31%
on 01/31/20
15.79 -14.82%
on 02/13/20
-1.18 (-8.07%)
since 01/17/20
3-Month
11.87 +13.31%
on 01/31/20
17.80 -24.44%
on 12/05/19
-0.15 (-1.10%)
since 11/18/19
52-Week
10.26 +31.09%
on 10/09/19
19.00 -29.21%
on 08/01/19
-0.54 (-3.86%)
since 02/15/19

Most Recent Stories

More News
Back from the Weekend and Back to New Highs

Back from the Weekend and Back to New Highs

SAVE : 42.59 (-2.94%)
DKS : 43.46 (-1.38%)
BBY : 90.16 (-0.06%)
ADNT : 27.86 (+0.76%)
AL : 43.50 (-3.95%)
MTW : 12.65 (-1.17%)
CAE : 30.40 (-0.46%)
OLED : 177.74 (+0.03%)
NTLA : 13.45 (-2.96%)
CRSP : 55.69 (-0.20%)
EDIT : 26.91 (+0.34%)
Implied Volatility Surging for Intellia (NTLA) Stock Options

Investors need to pay close attention to Intellia (NTLA) stock based on the movements in the options market lately.

NTLA : 13.45 (-2.96%)
Has Intellia Therapeutics (NTLA) Outpaced Other Medical Stocks This Year?

Is (NTLA) Outperforming Other Medical Stocks This Year?

NTLA : 13.45 (-2.96%)
Gene Therapy the Next Best Thing: Here's Why (Revised)

Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

NTLA : 13.45 (-2.96%)
VRTX : 245.93 (+0.87%)
QURE : 62.71 (-0.76%)
MGTX : 18.06 (-4.34%)
PIRS : 3.76 (+0.80%)
Gene Therapy the Next Best Thing: Here's Why

Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

NTLA : 13.45 (-2.96%)
VRTX : 245.93 (+0.87%)
QURE : 62.71 (-0.76%)
MGTX : 18.06 (-4.34%)
PIRS : 3.76 (+0.80%)
Don't Judge a Month by its First Day

Don't Judge a Month by its First Day

UAL : 80.24 (+0.87%)
BLDR : 27.27 (+0.29%)
TGT : 117.83 (+1.60%)
KBH : 39.66 (-0.28%)
NAVI : 14.30 (-1.85%)
HPE : 14.38 (-0.42%)
BBY : 90.16 (-0.06%)
DHI : 61.83 (+0.03%)
DKS : 43.46 (-1.38%)
NWL : 20.02 (-0.40%)
SYNA : 78.62 (-3.37%)
VGR : 13.42 (+0.30%)
CRSP : 55.69 (-0.20%)
EDIT : 26.91 (+0.34%)
NTLA : 13.45 (-2.96%)
Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data

Vertex (VRTX) and partner CRISPR Therapeutics announce positive early data from two studies on gene-editing drug CTX001 for the treatment of beta-thalassemia and sickle cell disease.

VRTX : 245.93 (+0.87%)
NTLA : 13.45 (-2.96%)
EDIT : 26.91 (+0.34%)
CRSP : 55.69 (-0.20%)
The NASDAQ Needs No Break

The NASDAQ Needs No Break

WYNN : 133.46 (+1.00%)
TAL : 57.96 (-1.96%)
CDAY : 74.12 (+0.60%)
ETSY : 53.32 (+0.30%)
MCD : 216.15 (-0.43%)
JCI : 41.99 (+0.07%)
FTNT : 119.45 (+0.22%)
URI : 153.98 (-1.84%)
SID : 3.02 (+3.78%)
ENTG : 56.40 (-3.03%)
LDOS : 123.22 (+9.23%)
MFC : 19.58 (-0.66%)
ROST : 122.49 (+0.58%)
SSW : 12.12 (-0.82%)
CRSP : 55.69 (-0.20%)
NTLA : 13.45 (-2.96%)
EDIT : 26.91 (+0.34%)
Axovant's GM1 Gangliosidosis Candidate Gets Orphan Drug Tag

The FDA grants Orphan Drug status to Axovant's (AXGT) gene therapy candidate, AXO-AAV-GM1, being developed for the treatment of GM1 gangliosidosis. Shares decline despite the positive news.

IDRA : 1.72 (+8.18%)
NTLA : 13.45 (-2.96%)
ANIK : 42.41 (+2.24%)
AXGT : 4.25 (-2.07%)
NASDAQ Hits New Record Despite Slow Session

NASDAQ Hits New Record Despite Slow Session

BA : 338.88 (-0.47%)
CMG : 927.56 (+0.61%)
TRWH : 29.70 (-0.10%)
CORE : 23.72 (-0.13%)
INXN : 92.97 (+0.78%)
WY : 30.12 (-1.76%)
BIDU : 134.18 (-0.29%)
HTHT : 35.50 (-3.82%)
WYNN : 133.46 (+1.00%)
YELP : 34.57 (-1.87%)
JD : 42.32 (+0.83%)
ESTC : 73.20 (+0.81%)
SDOW : 34.91 (+1.60%)
SQQQ : 16.45 (-0.24%)
GWPH : 124.16 (-2.31%)
NTLA : 13.45 (-2.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade NTLA with:

Business Summary

Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with...

See More

Key Turning Points

2nd Resistance Point 14.50
1st Resistance Point 13.98
Last Price 13.45
1st Support Level 13.05
2nd Support Level 12.64

See More

52-Week High 19.00
Fibonacci 61.8% 15.66
Fibonacci 50% 14.63
Fibonacci 38.2% 13.60
Last Price 13.45
52-Week Low 10.26

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar